|
JP6104806B2
(ja)
|
2010-10-06 |
2017-03-29 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
|
|
CN104244929B
(zh)
|
2012-04-16 |
2017-04-05 |
哈佛学院董事会 |
用于调节免疫反应的介孔二氧化硅组合物
|
|
PL2931738T3
(pl)
|
2012-12-13 |
2019-07-31 |
Aduro Biotech, Inc. |
Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania
|
|
US20160008399A1
(en)
|
2013-01-14 |
2016-01-14 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
|
|
WO2014179335A1
(en)
|
2013-04-29 |
2014-11-06 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
WO2014179760A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
|
RS59500B1
(sr)
|
2013-05-18 |
2019-12-31 |
Aduro Biotech Inc |
Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
EP3027227A4
(en)
|
2013-07-31 |
2018-05-23 |
Memorial Sloan Kettering Cancer Center |
Sting crystals and modulators
|
|
JP7348708B2
(ja)
|
2014-04-30 |
2023-09-21 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
組み合わせワクチン装置および癌細胞を殺滅する方法
|
|
PE20170198A1
(es)
|
2014-06-04 |
2017-04-08 |
Glaxosmithkline Ip Dev Ltd |
Dinucleotidos ciclicos como moduladores de sting
|
|
EP3546473B1
(en)
|
2014-12-16 |
2025-12-10 |
Kayla Therapeutics |
Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
HK1248603A1
(zh)
|
2015-03-10 |
2018-10-19 |
Aduro Biotech, Inc. |
用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
|
|
CA2982614A1
(en)
|
2015-05-07 |
2016-11-10 |
Baylor College Of Medicine |
Dendritic cell immunotherapy
|
|
WO2017011444A1
(en)
*
|
2015-07-13 |
2017-01-19 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating b cell cancers
|
|
CR20180101A
(es)
|
2015-08-13 |
2018-04-12 |
Merck Sharp & Dohme |
Compuestos di-nucleóticos cíclicos como agonistas de sting
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
EP3359675B1
(en)
|
2015-10-07 |
2024-01-03 |
Nant Holdings IP, LLC |
Activation of immune-related signalling pathways in cells via optofection
|
|
CA3002236A1
(en)
|
2015-10-28 |
2017-05-04 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
|
TWI704154B
(zh)
|
2015-12-03 |
2020-09-11 |
英商葛蘭素史克智慧財產發展有限公司 |
新穎化合物
|
|
RS67188B1
(sr)
|
2016-01-11 |
2025-10-31 |
Innate Tumor Immunity Inc |
Ciklični dinukleotidi za lečenje stanja povezanih sa aktivnošću sting kao što je kancer
|
|
WO2017123657A1
(en)
|
2016-01-11 |
2017-07-20 |
Gary Glick |
Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
|
|
WO2017123675A1
(en)
|
2016-01-11 |
2017-07-20 |
Synlogic, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
|
SG10201912074PA
(en)
|
2016-03-18 |
2020-02-27 |
Immune Sensor Llc |
Cyclic di-nucleotide compounds and methods of use
|
|
HRP20220936T1
(hr)
|
2016-04-07 |
2022-10-28 |
Glaxosmithkline Intellectual Property Development Limited |
Heterociklički amidi korisni kao modulatori proteina
|
|
JP2019510802A
(ja)
|
2016-04-07 |
2019-04-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
タンパク質調節物質として有用な複素環アミド
|
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
CN110418651A
(zh)
|
2016-08-02 |
2019-11-05 |
哈佛学院院长等 |
用于调节免疫应答的生物材料
|
|
FI3922279T3
(fi)
|
2016-08-30 |
2025-02-04 |
Dana Farber Cancer Inst Inc |
Lääkkeenantokoostumuksia ja niiden käyttötapoja
|
|
US20190345191A1
(en)
|
2016-08-31 |
2019-11-14 |
Innate Tumor Immunity, Inc. |
Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
|
|
US10414747B2
(en)
*
|
2016-10-04 |
2019-09-17 |
Merck Sharp & Dohme Corp. |
Benzo[b]thiophene compounds as sting agonists
|
|
EP3523314A1
(de)
|
2016-10-07 |
2019-08-14 |
Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH |
Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
|
|
WO2018100558A2
(en)
|
2016-12-01 |
2018-06-07 |
Takeda Pharmaceutical Company Limited |
Cyclic dinucleotide
|
|
WO2018118665A1
(en)
*
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Cyclic dinucleotide sting agonists for cancer treatment
|
|
US20190336532A1
(en)
*
|
2016-12-21 |
2019-11-07 |
Fred Hutchinson Cancer Research Center |
Scaffolds to treat solid tumor cells and escape variants
|
|
JP2020505016A
(ja)
*
|
2017-01-06 |
2020-02-20 |
シンロジック オペレーティング カンパニー インコーポレイテッド |
腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物
|
|
US11021511B2
(en)
|
2017-01-27 |
2021-06-01 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
US11492367B2
(en)
|
2017-01-27 |
2022-11-08 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
JP2020514321A
(ja)
|
2017-02-01 |
2020-05-21 |
モデルナティーエックス， インコーポレイテッド |
活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
|
|
US20200055883A1
(en)
|
2017-02-17 |
2020-02-20 |
Eisai R&D Management Co., Ltd. |
Cyclic di-nucleotides derivative for the treatment of cancer
|
|
JP2018131427A
(ja)
*
|
2017-02-17 |
2018-08-23 |
国立研究開発法人理化学研究所 |
免疫細胞の制御技術
|
|
MX2019012295A
(es)
|
2017-04-14 |
2020-02-07 |
Tollnine Inc |
Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
|
|
US11466047B2
(en)
|
2017-05-12 |
2022-10-11 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
WO2018232217A1
(en)
|
2017-06-16 |
2018-12-20 |
William Marsh Rice University |
Hydrogel delivery of sting immunotherapy for treatment of cancer
|
|
EP3431484A1
(en)
*
|
2017-07-21 |
2019-01-23 |
Ludwig-Maximilians-Universität München |
A fluorescent cyclic dinucleotide and its use in methods of identifying substances having an ability to modulate the cgas/sting pathway
|
|
US11312772B2
(en)
|
2017-08-04 |
2022-04-26 |
Merck Sharp & Dohme Corp. |
Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment
|
|
US11285131B2
(en)
|
2017-08-04 |
2022-03-29 |
Merck Sharp & Dohme Corp. |
Benzo[b]thiophene STING agonists for cancer treatment
|
|
US10947263B2
(en)
*
|
2017-08-31 |
2021-03-16 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
JP7270608B2
(ja)
*
|
2017-08-31 |
2023-05-10 |
エフ－スター・セラピューティクス・インコーポレイテッド |
化合物、組成物、及び疾患の治療方法
|
|
ES2904317T3
(es)
*
|
2017-08-31 |
2022-04-04 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticancerosos
|
|
CA3077337A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting)
|
|
US20210238172A1
(en)
|
2017-10-05 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators and methods of using the same
|
|
CN111194214A
(zh)
*
|
2017-10-05 |
2020-05-22 |
葛兰素史密斯克莱知识产权发展有限公司 |
施用sting激动剂的方法
|
|
JP7195317B2
(ja)
|
2017-11-10 |
2022-12-23 |
武田薬品工業株式会社 |
Ｓｔｉｎｇ調節剤化合物、ならびに製造及び使用する方法
|
|
EP3727401A4
(en)
|
2017-12-20 |
2022-04-06 |
Merck Sharp & Dohme Corp. |
CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
|
|
US10966999B2
(en)
|
2017-12-20 |
2021-04-06 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
WO2019134707A1
(zh)
*
|
2018-01-08 |
2019-07-11 |
成都先导药物开发股份有限公司 |
一种免疫调节剂
|
|
SG11202008636YA
(en)
|
2018-03-23 |
2020-10-29 |
Codiak Biosciences Inc |
Extracellular vesicles comprising sting-agonist
|
|
US20210015915A1
(en)
|
2018-03-23 |
2021-01-21 |
Takeda Pharmaceutical Company Limited |
Sting modulator compounds with sulfamate linkages, and methods of making and using
|
|
US11702430B2
(en)
|
2018-04-03 |
2023-07-18 |
Merck Sharp & Dohme Llc |
Aza-benzothiophene compounds as STING agonists
|
|
US10793557B2
(en)
|
2018-04-03 |
2020-10-06 |
Merck Sharp & Dohme Corp. |
Sting agonist compounds
|
|
US11874276B2
(en)
|
2018-04-05 |
2024-01-16 |
Dana-Farber Cancer Institute, Inc. |
STING levels as a biomarker for cancer immunotherapy
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
ES2929415T3
(es)
|
2018-05-25 |
2022-11-29 |
Incyte Corp |
Compuestos heterocíclicos tricíclicos como activadores de STING
|
|
MX2020012964A
(es)
|
2018-06-01 |
2021-02-16 |
Eisai R&D Man Co Ltd |
Metodos para el tratamiento de cancer de vejiga.
|
|
US11008344B2
(en)
|
2018-07-31 |
2021-05-18 |
Incyte Corporation |
Tricyclic heteroaryl compounds as STING activators
|
|
US10875872B2
(en)
|
2018-07-31 |
2020-12-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
|
MX2020013322A
(es)
|
2018-08-16 |
2021-02-22 |
Eisai R&D Man Co Ltd |
Sales de compuestos y cristales de los mismos.
|
|
EP3841112A1
(en)
|
2018-08-24 |
2021-06-30 |
Codiak BioSciences, Inc. |
Extracellular vesicles targeting dendritic cells and uses thereof
|
|
WO2020049534A1
(en)
*
|
2018-09-07 |
2020-03-12 |
Novartis Ag |
Sting agonist and combination therapy thereof for the treatment of cancer
|
|
AU2019344398B2
(en)
*
|
2018-09-21 |
2022-09-22 |
Shanghai De Novo Pharmatech Co., Ltd. |
Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
|
|
AU2019371206A1
(en)
|
2018-10-29 |
2021-05-27 |
Venenum Biodesign, LLC |
Novel sting agonists
|
|
US11110106B2
(en)
|
2018-10-29 |
2021-09-07 |
Venenum Biodesign, LLC |
Sting agonists for treating bladder cancer and solid tumors
|
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
|
US20220033431A1
(en)
*
|
2018-12-07 |
2022-02-03 |
Merck Sharp & Dohme Corp. |
Cyclic Di-Nucleotide Compounds as STING Agonists
|
|
US20220024964A1
(en)
*
|
2018-12-07 |
2022-01-27 |
Merck Sharp & Dohme Corp. |
Cyclic Di-Nucleotide Compounds as STING Agonists
|
|
US20220033435A1
(en)
*
|
2018-12-07 |
2022-02-03 |
Merck Sharp & Dohme Corp. |
Cyclic Di-Nucleotide Compounds as STING Agonists
|
|
US12129267B2
(en)
|
2019-01-07 |
2024-10-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
|
KR102620495B1
(ko)
*
|
2019-01-10 |
2024-01-04 |
셴젠 잉 바이오파마수티칼 씨오., 엘티디. |
시클릭 디뉴클레오티드 프로드러그 분자 및 이의 제조 방법과 응용
|
|
KR102707808B1
(ko)
|
2019-03-07 |
2024-09-19 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
|
|
EP3935066A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
KR20210141554A
(ko)
|
2019-03-21 |
2021-11-23 |
코디악 바이오사이언시즈, 인크. |
세포외 소포 접합체 및 이의 용도
|
|
CN114080232A
(zh)
|
2019-03-21 |
2022-02-22 |
科迪亚克生物科学公司 |
用于疫苗递送的细胞外囊泡
|
|
TW202104214A
(zh)
|
2019-04-05 |
2021-02-01 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
化合物
|
|
JP7621974B2
(ja)
|
2019-05-09 |
2025-01-27 |
アリゴス セラピューティクス インコーポレイテッド |
Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
|
|
US20220251200A1
(en)
|
2019-07-03 |
2022-08-11 |
Codiak Biosciences, Inc. |
Extracellular vesicles targeting t cells and uses thereof
|
|
AU2020310853A1
(en)
|
2019-07-05 |
2022-01-27 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
WO2021013234A1
(en)
*
|
2019-07-25 |
2021-01-28 |
Beigene, Ltd. |
Cyclic dinucleotides as sting agonists
|
|
US20220305048A1
(en)
|
2019-08-26 |
2022-09-29 |
Dana-Farber Cancer Institute, Inc. |
Use of heparin to promote type 1 interferon signaling
|
|
EP4034247A1
(en)
|
2019-09-25 |
2022-08-03 |
Codiak BioSciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
|
CA3152478A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Extracellular vesicle compositions
|
|
US20230103726A1
(en)
|
2019-09-25 |
2023-04-06 |
Codiak Biosciences, Inc. |
Methods of producing extracellular vesicles
|
|
US20220395465A1
(en)
|
2019-09-25 |
2022-12-15 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour
|
|
US20240165144A1
(en)
*
|
2019-10-16 |
2024-05-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating innate immune signaling pathways
|
|
CN114981265B
(zh)
|
2019-12-18 |
2025-01-03 |
Ctxt私人有限公司 |
化合物
|
|
US12251449B2
(en)
|
2019-12-19 |
2025-03-18 |
William Marsh Rice University |
Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
|
|
BR112022017136A2
(pt)
|
2020-02-28 |
2022-10-11 |
Tallac Therapeutics Inc |
Conjugação mediada por transglutaminase
|
|
WO2021184017A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicles for treating neurological disorders
|
|
JP2023518414A
(ja)
|
2020-03-20 |
2023-05-01 |
コディアック バイオサイエンシーズ， インコーポレイテッド |
治療のための細胞外小胞
|
|
WO2021216572A1
(en)
|
2020-04-20 |
2021-10-28 |
Massachusetts Institute Of Technology |
Lipid compositions for delivery of sting agonist compounds and uses thereof
|
|
JP7776145B2
(ja)
|
2020-05-13 |
2025-11-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
ポリマーマイクロデバイスの組成物およびがん免疫療法におけるその使用
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
EP4295917A3
(en)
|
2020-08-07 |
2024-02-28 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
|
CA3191593A1
(en)
|
2020-09-08 |
2022-03-17 |
Jinming Gao |
Polyvalent sting activating compositions and uses thereof
|
|
WO2022066883A1
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Extracellular vesicles comprising kras antigens and uses thereof
|
|
WO2022066898A2
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Methods of producing extracellular vesicles
|
|
WO2022094262A1
(en)
|
2020-10-30 |
2022-05-05 |
Avacta Life Sciences Limited |
Fap-activated serum extended half-life therapeutic conjugates
|
|
JP7397996B2
(ja)
|
2020-11-09 |
2023-12-13 |
武田薬品工業株式会社 |
抗体薬物コンジュゲート
|
|
GB202018665D0
(en)
*
|
2020-11-26 |
2021-01-13 |
Provost Fellows And Scholars Of Trinity College Dublin |
Immunotherapy for cancer
|
|
EP4046634A1
(en)
*
|
2021-02-17 |
2022-08-24 |
Centre national de la recherche scientifique |
Serca2 modulators and their therapeutic uses
|
|
JP7717832B2
(ja)
|
2021-04-10 |
2025-08-04 |
ジェンマブ エー／エス |
Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
|
|
EP4326769A1
(en)
|
2021-04-20 |
2024-02-28 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
|
EP4326321A1
(en)
|
2021-04-20 |
2024-02-28 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
|
WO2022226317A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
US12565681B2
(en)
*
|
2021-05-17 |
2026-03-03 |
China Medical University |
Method and a kit for predicting the susceptibility to stimulator of interferon genes (STING) agonists in a cancer patient
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
WO2023056468A1
(en)
|
2021-09-30 |
2023-04-06 |
Codiak Biosciences, Inc. |
Extracellular vesicle comprising cholesterol tagged sting-agonist
|
|
EP4687796A1
(en)
|
2023-04-05 |
2026-02-11 |
Massachusetts Institute of Technology |
Hybrid polymeric systems and methods of use thereof
|
|
AU2024353316A1
(en)
|
2023-09-26 |
2026-03-26 |
Genmab A/S |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025202222A1
(en)
*
|
2024-03-25 |
2025-10-02 |
Institut National de la Santé et de la Recherche Médicale |
Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
|